OTCM
VRCDF
Market cap5mUSD
Dec 26, Last price
0.11USD
Name
Verici Dx Plc
Chart & performance
P/E
—
P/S
49.15
EPS
—
Vol. 1Y
—
Shs. 5Y
55.85%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
4m
+12.04%
Net income
-7m
L+20.50%
CFO
-8m
L+39.41%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
Key people
Sara Barrington
Chief Executive Officer, Executive Director · since 2020
David Anderson
Company Secretary · since 2023
Aubrey Powell
Non-Executive Director · since 2025
Non-Executive Independent Chairman of the Board · since 2020
Senior Non-Executive Independent Director · since 2020
Lorenzo Gallon
Non-Executive Independent Director · since 2021
Erik Lium
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2020
Headquarters & legal address
Avon House, 19 Stanwell Road, Penarth,
CARDIFF CF64 2EZ
GB
CARDIFF CF64 2EZ
GB
Previous name
VERICI DX LIMITED
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||